<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554551</url>
  </required_header>
  <id_info>
    <org_study_id>FEO-PD</org_study_id>
    <nct_id>NCT03554551</nct_id>
  </id_info>
  <brief_title>Imaging the Vesicular Acetylcholine Transporter Using 18F-FEOBV PET in Parkinsons Disease</brief_title>
  <official_title>Imaging the Vesicular Acetylcholine Transporter Using 18Fluoro-fluoroethoxybenzovesamicol (18F-FEOBV) Positron Emission Tomography(PET) in Parkinsons Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Parkinson's disease (PD) often display symptoms, such as constipation, due to
      denervation of the cholinergic nerves in the gut. It has been hypothesized that PD initiates
      in the gut years prior to diagnosis. To gain a detailed understanding of the early stages of
      PD, techniques for quantification of cholinergic nerves are needed. The PET tracer 18F-FEOBV
      binds specifically to the vesicular acetylcholine transporter, situated in presynaptic
      cholinergic nerve terminals. The investigators will investigate 18F-FEOBV uptake in the brain
      and internal organs of 15 patients with moderate-stage PD and compare to 15 healthy controls.
      Furthermore, findings are correlated to validated clinical tests of the autonomic nervous
      system. The aim is to validate 18F-FEOBV PET/CT as a clinical imaging modality to diagnose
      parasympathetic denervation in PD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Density of vesicular acetylcholine transporter</measure>
    <time_frame>Day 1</time_frame>
    <description>Average density will be determined in each group for intestine, pancreas, suprarenal gland, heart and relevant areas of the brain. Group differences will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation to measurements of gastrointestinal denervation</measure>
    <time_frame>Day 1</time_frame>
    <description>Density of vesicular acetylcholine transporter will be correlated to symptoms of gastrointestinal autonomic denervation (constipation, gastroparesis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation to measurements of dysautonomia</measure>
    <time_frame>Day 1</time_frame>
    <description>Density of vesicular acetylcholine transporter will be correlated to measurements of dysautonomia (orthostatic hypotension, colon transit time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation to measurements of neuropsychological tests</measure>
    <time_frame>Day 1</time_frame>
    <description>Cerebral density of vesicular acetylcholine transporter is correlated with neuropsychological test scores.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Parkinsons disease</arm_group_label>
    <description>Disease duration &gt; 4 years, Hoehn &amp; Yahr stage 2-3, 50-85 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>50-85 years</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson patients are moderate stage disease. Healthy subjects have to meet the criteria
        below.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinsons disease, disease duration &gt; 4 years, Hoehn &amp; Yahr stage 2-3

        Exclusion Criteria:

          -  Significant neurological diseases (e.g. stroke, tumor)

          -  Significant psychiatric disease

          -  Previous major surgery on thoracic and/or abdominal organs

          -  Significant medical disease (e.g. heart- or liver failure)

          -  Inflammatory bowel disease

          -  Gluten intolerance

          -  Diabetes

          -  Magnetic Resonance (MR) contraindications (metal in body, claustrophobia)

          -  Allergy to CT-contrast fluid

          -  Pacemaker

          -  Any current or previous cancer involving internal organs

          -  Peripheral neuropathy (except Parkinsons disease related)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacob Horsager, M.D.</last_name>
    <phone>+4526819204</phone>
    <email>jacobnls@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Borghammer, MD, DMSc, PhD</last_name>
    <phone>+4528261039</phone>
    <email>perborgh@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Region Midt</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Horsager, MD</last_name>
      <phone>0045 26819204</phone>
      <email>jacobnls@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Per Borghammer</last_name>
      <email>perborgh@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Jacob Horsager</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Parasympathetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

